102 SYNERGISTIC INTERACTION BETWEEN ETOPOSIDE AND 1-β-D-ARABINOFURANOSYLCYTOSINE

Shirakawa Cell Cycle - d - Arabinofuranosylcytosine in the β The Locus of Action of 1 - Updated

son Hospital. The cultures were maintained in McCoy's 5A medium reconstituted from powder (Grand Island Biological Company) not containing antibiotics. The medium was supple mented with 20% fetal calf serum (Hyland). The cultures were fed daily and subcultured at least every two days. son Hospital. The KB cells were maintained in minimal essen tial medium (Eagle's) obtained in powdered form fro...

Close Correlation of 1-β-D-Arabinofuranosylcytosine 5'-Triphosphate, an Intracellular Active Metabolite, to the Therapeutic Efficacy of N4-Behenoyl-1-β-D-arabinofuranosylcytosine Therapy for Acute Myelogenous Leukemia

Ras oncogene-induced sensitization to 1-beta-D-arabinofuranosylcytosine.

Human tumor cells containing ras oncogenes display enhanced sensitivity to 1-beta-D-arabinofuranosylcytosine (Ara-C) and other deoxycytidine analogues (H-M. Koo, et al., Cancer Res., 56: 5211-5216, 1996). Human tumor cell lines with or without a ras oncogene as well as a pair of isogenic cell lines with one containing an activated ras oncogene were used to study the basis for differential sensi...

Bone Marrow Cell Kinetics Scheduled Dosing Intervals Based on Direct Measurements of - d - Arabinofuranosylcytosine Efficacy by β Increasing 1 - Updated

The therapeutic efficacy of cell cycle phase-specific drugs can be im proved by repeated administrations, the dosing interval being related to the cell cycle time of the susceptible normal host tissue. Kinetic measure ments of bone marrow cell proliferation, with bromodeoxyuridine labeling and flow cytometry analysis, were used to determine the optimal dosing intervals of 1-@3-D-arablnofuranosy...

Outcome of treatment with EMA/EP (etoposide methotrexate and actinomycin-D/ etoposide and cisplatin) regimen in gestational trophoblastic neoplasia

Background: Gestational trophoblastic neoplasia (GTN) originates from placental trophoblast and is a highly chemosensitive and curable gynecologic malignancy. The present study was conducted to evaluate the effectiveness and safety of EMA/EP (etoposide, methotrexate, actinomycin-D, etoposide, and cisplatin) regimen in the treatment of high-risk GTN as well as patients’ outcome.  &nb...